Global Myelodysplastic Syndrome Therapeutics Market 2018-2022

About Myelodysplastic Syndrome Therapeutics
Myelodysplastic syndrome (MDS) includes a group of clonal myeloid neoplasms characterized by cytopenia due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evolution and progression to AML.

Technavio’s analysts forecast the global myelodysplastic syndrome therapeutics market to grow at a CAGR of 2.54% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global myelodysplastic syndrome therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of patented and generic drugs used to treat MDS.
The market is divided into the following segments based on geography:
‧ Americas
‧ APAC
‧ EMEA

Technavio's report, Global Myelodysplastic Syndrome Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
‧ Celgene
‧ Otsuka
‧ Novartis

Market driver
‧ Improved prognostic classification of MDS through advanced technologies
‧ For a full, detailed list, view our report

Market challenge
‧ Inadequacies in treatment landscape of MDS
‧ For a full, detailed list, view our report

Market trend
‧ High incidence in older adult population
‧ For a full, detailed list, view our report

Key questions answered in this report
‧ What will the market size be in 2022 and what will the growth rate be?
‧ What are the key market trends?
‧ What is driving this market?
‧ What are the challenges to market growth?
‧ Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.